MX395730B - Uso de lavados alcalinos durante la cromatografia para remover impurezas. - Google Patents

Uso de lavados alcalinos durante la cromatografia para remover impurezas.

Info

Publication number
MX395730B
MX395730B MX2017011121A MX2017011121A MX395730B MX 395730 B MX395730 B MX 395730B MX 2017011121 A MX2017011121 A MX 2017011121A MX 2017011121 A MX2017011121 A MX 2017011121A MX 395730 B MX395730 B MX 395730B
Authority
MX
Mexico
Prior art keywords
remove impurities
protein
interest
during chromatography
chromatography matrix
Prior art date
Application number
MX2017011121A
Other languages
English (en)
Spanish (es)
Other versions
MX2017011121A (es
Inventor
Jue Wang
Krina Patel
Neil E Jaffe
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2017011121A publication Critical patent/MX2017011121A/es
Publication of MX395730B publication Critical patent/MX395730B/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/50—Conditioning of the sorbent material or stationary liquid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
MX2017011121A 2015-03-13 2016-03-11 Uso de lavados alcalinos durante la cromatografia para remover impurezas. MX395730B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562132974P 2015-03-13 2015-03-13
PCT/US2016/021984 WO2016149088A1 (en) 2015-03-13 2016-03-11 Use of alkaline washes during chromatography to remove impurities

Publications (2)

Publication Number Publication Date
MX2017011121A MX2017011121A (es) 2017-11-28
MX395730B true MX395730B (es) 2025-03-25

Family

ID=55699796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011121A MX395730B (es) 2015-03-13 2016-03-11 Uso de lavados alcalinos durante la cromatografia para remover impurezas.

Country Status (13)

Country Link
US (2) US10695693B2 (enExample)
EP (2) EP4194071A1 (enExample)
JP (1) JP6807859B2 (enExample)
KR (1) KR102490956B1 (enExample)
CN (1) CN107636005B (enExample)
AU (2) AU2016233557B2 (enExample)
BR (1) BR112017018365A2 (enExample)
CA (1) CA2978095C (enExample)
EA (1) EA035635B1 (enExample)
IL (1) IL254372B (enExample)
MX (1) MX395730B (enExample)
SG (2) SG10201908027QA (enExample)
WO (1) WO2016149088A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738078B2 (en) * 2014-11-03 2020-08-11 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
BR112017018365A2 (pt) 2015-03-13 2018-04-10 Bristol-Myers Squibb Company uso de lavagens alcalinas durante cromatografia para remoção de impurezas
CA3233933A1 (en) 2017-01-30 2018-08-02 Regeneron Pharmaceuticals, Inc. Compositions and methods for reducing bioburden in chromatography
WO2019246153A1 (en) * 2018-06-19 2019-12-26 Bristol-Myers Squibb Company Methods of purifying proteins using chromatography
SG11202101369XA (en) * 2018-08-17 2021-03-30 Regeneron Pharma Method and chromatography system for determining amount and purity of a multimeric protein
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CA3116717A1 (en) * 2018-10-31 2020-05-07 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
US20210380638A1 (en) * 2018-12-21 2021-12-09 WuXi Biologics Ireland Limited A method for improving aggregate removal by Protein A chromatography
SG11202106370WA (en) 2019-01-16 2021-07-29 Regeneron Pharma Method and system of identifying and quantifying antibody fragmentation
CN109870428A (zh) * 2019-01-21 2019-06-11 江苏华泰疫苗工程技术研究有限公司 一种基于表面等离子共振技术的抗体定量检测方法
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
KR20260058863A (ko) * 2019-09-24 2026-04-29 리제너론 파아마슈티컬스, 인크. 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
CN114599971A (zh) * 2019-10-14 2022-06-07 皮尔斯生物科技有限公司 肽纯化配制物和方法
JP7817945B2 (ja) * 2020-03-27 2026-02-19 ハエマロジックス・リミテッド 組成物および方法
PE20231507A1 (es) * 2020-10-02 2023-09-26 Lilly Co Eli Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped
TW202600582A (zh) * 2024-02-20 2026-01-01 美商艾克塞里克斯公司 用於蛋白質純化之方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPS63276494A (ja) * 1987-02-26 1988-11-14 ダナーファーバー・キャンサー・インスチチュート・インコーポレーテッド Lfa−3の精製法
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
CA1323567C (en) * 1987-10-05 1993-10-26 Gene R. Nathans Method for purification of antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
ATE370961T1 (de) * 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1472275B1 (en) 2002-02-05 2008-12-17 Genentech, Inc. Protein purification
US7763706B1 (en) * 2003-07-17 2010-07-27 Campina B.V. Arginine/lysine-enriched peptides
BRPI0415887B1 (pt) * 2003-10-27 2021-01-26 Wyeth métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita
EP1874825B1 (en) * 2005-04-26 2010-03-24 Sandoz AG Affinity ligands
US8263750B2 (en) * 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
JP2010501623A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Fc含有タンパク質の精製法
TW200821026A (en) 2006-09-08 2008-05-16 Wyeth Corp Arginine wash in protein purification using affinity chromatography
HUE024877T2 (en) * 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
CA2932207A1 (en) * 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
BR112012014937B1 (pt) 2009-12-18 2021-01-19 Novartis Ag método de produção de um anticorpo, fragmento de anticorpo ou proteína de fusão fc purificada usando uma matriz de cromatografia de afinidade
JP2012001462A (ja) * 2010-06-15 2012-01-05 Kaneka Corp 抗体精製用カラム
KR101953405B1 (ko) 2011-06-01 2019-02-28 노파르티스 아게 친화성 크로마토그래피를 위한 세척 용액 및 방법
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
WO2016031932A1 (ja) 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるFc領域を有するタンパク質の製造方法
BR112017018365A2 (pt) 2015-03-13 2018-04-10 Bristol-Myers Squibb Company uso de lavagens alcalinas durante cromatografia para remoção de impurezas

Also Published As

Publication number Publication date
IL254372A0 (en) 2017-11-30
CN107636005A (zh) 2018-01-26
MX2017011121A (es) 2017-11-28
KR102490956B1 (ko) 2023-01-19
CN107636005B (zh) 2021-07-16
SG11201707330RA (en) 2017-10-30
US12157073B2 (en) 2024-12-03
US10695693B2 (en) 2020-06-30
CA2978095C (en) 2022-02-15
KR20170125948A (ko) 2017-11-15
IL254372B (en) 2022-05-01
AU2016233557B2 (en) 2021-06-24
SG10201908027QA (en) 2019-10-30
EP4194071A1 (en) 2023-06-14
EA201792012A1 (ru) 2018-01-31
EP3268100A1 (en) 2018-01-17
BR112017018365A2 (pt) 2018-04-10
AU2016233557A1 (en) 2017-11-02
US20200282332A1 (en) 2020-09-10
JP2018510867A (ja) 2018-04-19
WO2016149088A1 (en) 2016-09-22
AU2021221870A1 (en) 2021-09-23
US20180078876A1 (en) 2018-03-22
JP6807859B2 (ja) 2021-01-06
CA2978095A1 (en) 2016-09-22
EA035635B1 (ru) 2020-07-17

Similar Documents

Publication Publication Date Title
SG10201908027QA (en) Use of alkaline washes during chromatography to remove impurities
MX2016017115A (es) Metodos y reactivos para la purificacion de proteinas.
MX392628B (es) Amortiguador de lavado de cromatografia de afinidad.
PE20142451A1 (es) Composiciones de conjugados de xten y metodos para realizar las mismas
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
MX2019015304A (es) Amortiguador de lavado para cromatografia de intercambio cationico.
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
CU20170039A7 (es) Método de purificación del anticuerpo humanizado 9e4
WO2015191911A3 (en) Protein enriched microvesicles and methods of making and using the same
WO2015195453A3 (en) Methods for increasing the capacity of flow-through processes
SG194460A1 (en) Wash solution and method for affinity chromatography
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
CR20200234A (es) POLIPÉPTIDO PARA LA ESCISIÓN DE ZEARALENONA Y/O DERIVADOS DE LA ZEARALENONA, POLINUCLEÓTIDOS AISLADOS DEL MISMO, Y ADITIVO POLIPÉPTIDO QUE CONTIENE, USO DE DICHO POLIPÉPTIDO Y MÉTODO (Divisional 2016-0128)
CL2020000087A1 (es) Cromatografía.
TR201911082T4 (tr) K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem.
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
EP4389757A3 (en) Methods for purifying antibodies
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
EA201892643A1 (ru) Способ очистки и активации ботулинического нейротоксина
MX388197B (es) Método para la reducción de proteínas de células hospederas en cromatografía de afinidad.
AR104358A1 (es) Método para la purificación de proteínas
MY181081A (en) Method for purifying antibody having low isoelectric point
EA201691834A1 (ru) Новый способ очистки гонадотропина
BR112017025872A2 (pt) proteínas de ligação multiespecíficas